To view this email as a web page, click here.
June 18, 2019
 
Linagliptin Found Safe in T2DM Patients at High Cardiorenal Risk
ADA 2019—In a subanalysis of the CARMELINA study, the DPP-4 inhibitor linagliptin showed similar risk for first or recurrent CV events or hospitalization vs placebo in T2DM patients with high cardiorenal risk.
(©Nerthuz/Shutterstock.com)

Read more
 
ADVERTISEMENT
SGLT2 Inhibitor Reduces CV, Renal Events in Type 2 Diabetes
ADA 2019—Dapagliflozin reduced CV death, hospitalization for HF, and progression of CKD among T2DM patients with a wide distribution of baselines CVD risk in DECLARE-TIMI 58.

Read more
 
 
PLUS: More on Cardiovascular Outcomes Trials on Patient Care
 
Diabetes Drugs and Cardioprotection: 8 Questions on Key Trials
 
ACC 2019: 3 Studies in Cardioprotection
 
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.